pf-03550096 pf-03550096 pf-03550096 is a drug that acts as a potent agonist for the cb2 cannabinoid receptor, with good selectivity over cb1 having ki values of 7nm at cb2 and 1500nm at cb1. it was originally developed by pfizer in 2008 as a medication for irritable bowel syndrome, but has only progressed to animal studies. pf-03550096identifiers iupac name n--2,3-dihydro-3-(3-hydroxy-3-methylbutyl)-2-oxo-1h-benzimidazole-1-carboxamide cas number910376-39-5 ypubchem cid24857887chemspider21378519uniie8s33vnw75comptox dashboard (epa)dtxsid001010008 chemical and physical dataformulac19h28n4o4molar mass376.457 g·mol−13d model (jsmol)interactive image smiles o=c(n1c(n(ccc(c)(o)c)c2=c1c=cc=c2)=o)n(c(c)(c)c)c(n)=o inchi inchi=1s/c19h28n4o4/c1-18(2,3)14(15(20)24)21-16(25)23-13-9-7-6-8-12(13)22(17(23)26)11-10-19(4,5)27/h6-9,14,27h,10-11h2,1-5h3,(h2,20,24)(h,21,25)/t14-/m1/s1key:ggnifxbijcnxct-cqszacivsa-n